Selected CYP2C8 Substrates/Leflunomide; Teriflunomide
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Moderate. These medicines may cause some risk when taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Leflunomide and teriflunomide may slow down how quickly your body processes paclitaxel, pioglitazone, repaglinide, or rosiglitazone.
What might happen:
The amount of paclitaxel, pioglitazone, repaglinide, or rosiglitazone in your blood may increase. You may experience more side effects from these agents than expected.
What you should do about this interaction:
Let your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together or if you have used leflunomide or teriflunomide in the previous two years. Your doctor may want to check the amount of your medicine in your blood or change the dose of your medicine. If you are taking pioglitazone, repaglinide, or rosiglitazone, you may need to monitor your blood sugar more often.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
1.Aubagio (teriflunomide) US prescribing information. Genzyme Corporation September, 2012.
2.US Food and Drug Administration (FDA). Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/D rugInteractionsLabeling/ucm093664.htm. Updated 08/05/2011.